These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 16945052

  • 1. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis.
    McCall KL, Craddock D, Edwards K.
    Pharmacotherapy; 2006 Sep; 26(9):1297-306. PubMed ID: 16945052
    [Abstract] [Full Text] [Related]

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.
    Abuissa H, Jones PG, Marso SP, O'Keefe JH.
    J Am Coll Cardiol; 2005 Sep 06; 46(5):821-6. PubMed ID: 16139131
    [Abstract] [Full Text] [Related]

  • 4. Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure.
    Tsuchihashi-Makaya M, Furumoto T, Kinugawa S, Hamaguchi S, Goto K, Goto D, Yamada S, Yokoshiki H, Takeshita A, Tsutsui H, JCARE-CARD Investigators.
    Hypertens Res; 2010 Mar 06; 33(3):197-202. PubMed ID: 19960016
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.
    Epstein BJ, Gums JG.
    Ann Pharmacother; 2005 Mar 06; 39(3):470-80. PubMed ID: 15701766
    [Abstract] [Full Text] [Related]

  • 6. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials).
    Andraws R, Brown DL.
    Am J Cardiol; 2007 Apr 01; 99(7):1006-12. PubMed ID: 17398202
    [Abstract] [Full Text] [Related]

  • 7. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
    Ong HT.
    J Am Board Fam Med; 2009 Apr 01; 22(6):686-97. PubMed ID: 19897698
    [Abstract] [Full Text] [Related]

  • 8. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes.
    Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avorn J.
    Am J Kidney Dis; 2005 Dec 01; 46(6):1080-7. PubMed ID: 16310574
    [Abstract] [Full Text] [Related]

  • 9. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR, Romero B, Fernandez-Carbonero E, Sánchez-Casado E, Cubero JJ.
    J Renin Angiotensin Aldosterone Syst; 2009 Dec 01; 10(4):195-200. PubMed ID: 20026868
    [Abstract] [Full Text] [Related]

  • 10. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.
    Kuti EL, Baker WL, White CM.
    Curr Med Res Opin; 2007 Jun 01; 23(6):1239-44. PubMed ID: 17559720
    [Abstract] [Full Text] [Related]

  • 11. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
    Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, Conte G.
    Am J Kidney Dis; 2008 Sep 01; 52(3):475-85. PubMed ID: 18468748
    [Abstract] [Full Text] [Related]

  • 12. Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials.
    McFarlane SI.
    Expert Rev Cardiovasc Ther; 2009 Nov 01; 7(11):1363-71. PubMed ID: 19900019
    [Abstract] [Full Text] [Related]

  • 13. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
    Volpe M, Tocci G, Sciarretta S, Verdecchia P, Trimarco B, Mancia G.
    J Hypertens; 2009 May 01; 27(5):941-6. PubMed ID: 19381108
    [Abstract] [Full Text] [Related]

  • 14. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA, Molnar J, Arora RR.
    Diabetes Obes Metab; 2008 Jan 01; 10(1):41-52. PubMed ID: 18095949
    [Abstract] [Full Text] [Related]

  • 15. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan 01; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 16. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA.
    Am J Cardiol; 2007 Aug 06; 100(3A):45J-52J. PubMed ID: 17666198
    [Abstract] [Full Text] [Related]

  • 17. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 18. The role of renin blockers in the prevention of diabetes.
    Alkhenizan AH, Alswes MA.
    Saudi Med J; 2007 Jan 21; 28(1):91-5. PubMed ID: 17206297
    [Abstract] [Full Text] [Related]

  • 19. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M, Solomon SD.
    Curr Opin Cardiol; 2006 Jul 21; 21(4):268-72. PubMed ID: 16755193
    [Abstract] [Full Text] [Related]

  • 20. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
    Bommer WJ.
    Prev Cardiol; 2008 Jul 21; 11(4):215-22. PubMed ID: 19476574
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.